cost-effectiveness of sequential adjuvant therapy vs. monotherapies with aromatase inhibitors (AI) or tamoxifen in postmenopausal women with Early-Stage breast cancer from the Mexican health care payer's perspective. METHODS: We used a ten-year Markov analysis model to estimate costs and effectiveness. Effectiveness measure was the % of patients free of recurrence (local or distant). Transition probabilities were obtained from international published literature. Comparators were: tamoxifen 20 mg/day (five years); anastrozole 1 mg/day (five years); letrozole 2.5 mg/day (five years) and the sequential therapy with tamoxifen 20 mg/day (2.5-years) + exemestane 25 mg/day (five-years). Resource use estimations were performed employing hospital records in an oncology hospital from the Social Security Mexican Institute-IMSS in Mexico City (n = 104). They included emergency, surgery, chemotherapy, outpatient and inpatient services, drugs, oncology procedures, etc. Costs and effectiveness measures were discounted 3% annually. One-way and probabilistic sensitivity analyses were performed and acceptability curves were constructed. RESULTS: Sequential therapy with tamoxifen followed by cross over to exemestane at 2.5years yielded 84.2% of patients free of recurrence in the tenyears analysis followed of the two other AI monotherapies (81.6%) and tamoxifen monotherapy (79.5%). The latter showed the lower expected costs (US$23,968.3) followed by the sequential therapy (US$29,077.3), anastrozole (US$30,615.2) and letrozole (US$31,478.3). Sequential therapy was the option most cost effective compared to AI monotherapies. Results were robust to Monte Carlo second order sensitivity analysis. Acceptability curves showed the same results with a mean of 83.7% of certainty. CONCLUSION: Sequential therapies should be considered as options more cost-effective compared to monotherapies. These results should be taken into account by Mexican clinicians in the management of these patients.
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COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING
Orlewska E 1 , Pienkowski T 2 , Drosik K 3 , Gyldmark M 4 , Aultman R 5 , Szkultecka-Debek M 6 1 Centrum Farmakoekonomiki, Warsaw, Poland, 2 Cancer Center-M.Sklodowska -Curie Memorial Institute of Oncology, Warsaw, Poland, 3 Regional Cancer Center, Opole, Poland, 4 F. Hoffmann La Roche, Basel, Switzerland, 5 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6 Roche Polska Sp. z o.o, Warsaw, Poland OBJECTIVES: To estimate cost-effectiveness of adjuvant trastuzumab for one year following standard chemotherapy in HER2-positive early breast cancer (EBC) versus standard therapy alone (observation). METHODS: Markov model was developed based on results of pivotal clinical study (HERA). The health states included disease free survival, recurrence (local, contralateral), distant metastases, cardiac adverse events and death. The cohort simulation starts with 50-year-old patients who are considered disease free, i.e. have undergone surgery, chemo-and/or radiotherapy. Effectiveness was measured in terms of QALY gained. Population-based utilities were derived from published literature. Yearly costs of each health state were established based on the opinion of Polish experts from two oncology centers and reported in PLN (1 EUR = 3.8 PLN in 2006). Direct medical costs and outcomes were projected over patients' lifetimes from a Polish health care payer's perspective, using 5% discount rate for both or costs only. Probabilistic sensitivity analysis was performed. RESULTS: The total lifetime costs/patient were estimated to be 198,294 PLN in trastuzumab and 62,812 PLN in no-trastuzumab arm respectively. The main cost driver was the aquisition cost of trastuzumab. The total QALYs generated with trastuzumab treatment were 9.53 vs 7.5 for no trastuzumab treatment (discounted) and 16.56 vs 11.9 QALY (without discounting) respectively. This results in ICER for trastuzumab of 66,746 PLN/QALY (discounted) and 30,769 PLN/QALY (with only costs discounted). Probabilistic sensitivity analysis showed that for 50% simulations the ICER remained below 60,000 PLN/QALY and for 97.5%below 88,624 PLN/QALY. CONCLUSION: The use of trastuzumab in EBC improves QALYs compared to observation alone. Considering the suggested threshold for cost-effectiveness, calculated on the basis of one-year haemodialysis treatment costs (60,000-74,700 PLN), adjuvant therapy with trastuzumab appears to be cost-effective treatment for patients with HER2positive EBC in Poland.
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COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN FOR THE TREATMENT OF POST MENOPAUSAL HORMONE-RECEPTOR POSITIVE BREAST CANCER (BC) IN THE ADJUVANT SETTING IN BRAZIL
Fonseca M 1 , Araujo G 1 , Saad E 2 1 Axia.Bio Consulting, São Paulo, Brazil, 2 Dendrix, São Paulo, Brazil OBJECTIVES: Anastrozole primary adjuvant therapy compared to tamoxifen significantly improves disease free survival (DFS) and time to recurrence (TTR) and significantly reduces distant metastases and contralateral breast cancers in PM women with hormone-receptor positive early BC. METHODS: We developed a Markov model describing the clinical history of PM women with early BC that projected improvements in lifetime life years gained (LYG), long-term costs, and cost-effectiveness of the adjuvant treatment with anastrozole compared to that with tamoxifen. The base case was a 64-year-old PM women with hormone-receptor positive BC submitted to mastectomy and without metastases. Transition probabilities came from the ATAC study and other major studies from the medical literature. The local management and costs of each health state was based on a Delphi panel according to the private health care perspective. Outcomes were discounted at 3% annually. Sensitivity analyses and a second order Monte Carlo simulation were performed. RESULTS: The lifetime horizon analysis showed: Anastrozole in comparison to tamoxifen increased life expectancy (LY) in 0,55 year; the incremental cost per LYG was R$27.693,36; the tamoxifen group expenses in comparison to the anastrozole group in recurrence states (loco-regional disease and metastasis) and with adverse events were respectively 17% and 16% higher. CONCLUSION: Improvements in DFS and TTR with primary adjuvant anastrozole in postmenopausal women with operable hormone-receptor positive breast cancer improves patient outcomes in terms of LYG with an acceptable cost-effectiveness ratio in Brazil.
PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLY-STAGE BREAST CANCER RECEIVING CHEMOTHERAPY
